Search - tctmd.com

Displaying 401 - 420 of 574

Sort: Relevancy | Date

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Presenter: Matthew J. Price, Jason H. Rogers, Petr Neuzil

October 30, 2016

Presentation TCT 2016

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

Presenter: Matthew J. Price, Jason H. Rogers

October 30, 2016

Presentation TCT 2016

LAA Closure: What Have We Learned 18 Months After Approval?

Presenter: Sarah Clarke, Saibal Kar

October 30, 2016

Presentation TCT 2016

LAA Closure Review: Brief Review of Anatomy, Rationale, and Trial Results

Presenter: Sarah Clarke, Jessica Forman

October 30, 2016

Presentation TVT 2016

Real-World Applications of Transcatheter LAA Closure: Defining the Indications and Techniques

Presenter: Saibal Kar

June 18, 2016

Presentation TVT 2016

Concomitant (or Sequential) Procedures During Transcatheter Mitral Repair: Time to Consider LAA Closure?

Presenter: Fabian Nietlispach

June 16, 2016

Presentation Scripps 2016

Putting It All Together: Warfarin, NOAC or LAA Closure?

Presenter: Brian K. Whisenant

February 04, 2016

Presentation Scripps 2016

LAA Closure Fundamentals: Keys to a Successful Procedure

Presenter: Matthew J. Price

February 04, 2016

Presentation Scripps 2016

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

Presenter: Brian Whisenant

February 04, 2016

Presentation Scripps 2016

LAA Closure for Stroke Prevention: Rationale and Identifying the Patient Who Might Benefit

Presenter: Brian K. Whisenant

February 03, 2016

Presentation Scripps 2016

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

Presenter: Brian K. Whisenant

February 03, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Advertisement

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Cases #7 and #8: When LAA closure Was Unsuccessful - Lessons Learned

Cases #3 and #4: Transseptal Puncture for LAA Closure - When Location Makes a Difference

LAA Closure: What Have We Learned 18 Months After Approval?

LAA Closure Review: Brief Review of Anatomy, Rationale, and Trial Results

Real-World Applications of Transcatheter LAA Closure: Defining the Indications and Techniques

Concomitant (or Sequential) Procedures During Transcatheter Mitral Repair: Time to Consider LAA Closure?

Putting It All Together: Warfarin, NOAC or LAA Closure?

LAA Closure Fundamentals: Keys to a Successful Procedure

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

LAA Closure for Stroke Prevention: Rationale and Identifying the Patient Who Might Benefit

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content